Using RWD for drug approval

Topics and speakers:

RWD in regulatory processes, hurdles and possibilities from the Regulatory Authority perspective

Anja Schiel, Special Adviser and Lead Methodologist in Regulatory and Pharmacoeconomic Statistics, Norwegian Medicines Agency

RWD: The perspective from a Pharmaceutical company

Leah Burns, Director, WW HEOR, RWE Strategy, Bristol Myers Squibb, USA

Please note: This is a CONNECT internal, closed meeting. CONNECT Partners receive a personal calendar invite / email invitation. If you are a CONNECT Partners and haven't received an invite, please contact Jutta Heix (jh@oslocancercluster.no).